Skip to main content
AAO-HNSF 2025 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Panel Presentations

Rhinology/Allergy

Biologics for Chronic Sinusitis: Is Sinus Surgery Becoming Obsolete?

Tuesday, October 14, 2025
8:00 AM - 9:00 AM EDT
Location: 126
Disclosure(s):
Mohamad R. Chaaban, MD, MSCR, MBA:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Justin H. Turner, MD, PhD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Sarah K. Wise, MD, MSCR:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: The use of biologics in chronic rhinosinusitis represents a critical knowledge gap, as identified by the AAO-HNSF academy for 2025. These therapies have only recently been approved for chronic rhinosinusitis with nasal polyps in 2019, despite their established use in other conditions. This program aims to provide a comprehensive overview of the evolving landscape of biologic treatments for chronic sinusitis.

A panel of expert faculty will discuss real-world cases, management approaches, and clinical protocols, incorporating both European and U.S. perspectives on patient care. Key topics will include:

Cost and Accessibility: Insights into financial considerations and healthcare access.
Side Effect Management: A detailed review of adverse effects and mitigation strategies.
Multidisciplinary Care: The role of collaborative approaches with other medical experts.
The program will also explore the future of biologic therapies, including emerging treatments, their mechanisms of action, and the potential development of targeted biologics for patients with type 2 inflammation but without nasal polyposis.

This discussion-based session is ideal for healthcare providers seeking to enhance their understanding of biologic therapies and their application in chronic sinusitis management.

OUTCOME OBJECTIVE 1: Analyze the clinical application of biologic therapies in chronic rhinosinusitis, including their approval, efficacy, and safety considerations

OUTCOME OBJECTIVE 2: Evaluate strategies to address cost, accessibility, and side effect management in the use of biologics

OUTCOME OBJECTIVE 3: Examine the future of biologic therapies, including emerging treatments and their potential for broader applications in patients with type 2 inflammation.

BACKGROUND STATEMENT: The rising use of biologics in chronic rhinosinusitis addresses a critical knowledge gap, with recent approvals and evolving treatments requiring clinicians to understand cost, safety, and multidisciplinary approaches for improved patient outcomes

Comprehensive Otolaryngology Track Statement :

    Moderator(s)

  • MC

    Mohamad R. Chaaban, MD, MSCR, MBA

    Associate Professor
    Cleveland Clinic
    Cleveland, OH, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

    • Panelist(s)

  • OA

    Omar G. Ahmed, MD

    Assistant Professor
    Houston Methodist Hospital
    Houston, Texas, United States

    Disclosure information not submitted.

  • JT

    Justin H. Turner, MD, PhD

    Professor and Chair
    University of Alabama at Birmingham (UAB)
    Birmingham, AL, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • Sarah K. Wise, MD, MSCR

    Professor of Otolaryngology
    Emory University School of Medicine
    Atlanta, GA, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.